ArticleAddiction & health2026
Dopamine D2 Receptor and Dopamine Transporter mRNA Expression in Addicted Peripheral Blood Lymphocytes.
Article in Addiction & health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to detect the effects of opioid addiction on the mRNA expression levels of the dopamine D2 receptor (DRD2) and dopamine transporter (DAT) in peripheral blood leukocytes. Methods: Four groups, each comprising 30 individuals, were included in the study: opioid-addicted, methadone-maintained (MM), long-term abstinent, and normal subjects. We measured the mRNA levels of DRD2 and DAT in peripheral blood leukocytes via real-time quantitative reverse transcription‒polymerase chain reaction (real-time RT‒PCR). Findings: The results of the study showed that DAT mRNA expression was not statistically significant in the affected subjects compared to the control group. Regarding DRD2, mRNA expression was increased significantly in the MM subjects compared to the control group ( Conclusion: Our study could guide further research to refine the clinical applicability of biomarkers related to dopamine signaling proteins in opioid addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.